(1) The board or their designee(s) may review and compile information contained in the registry to identify evidence of possible misuse or diversion of controlled substances.
(2) In instances of possible misuse or diversion, the executive director will promptly report by telephone, e-mail, or postal mail the patient's profile information to practitioners and pharmacists who have provided care to that patient.
(3) The following factors are suggestive, but not conclusive evidence of misuse or diversion:
(a) four or more prescribers in a 60-day period; or
(b) four or more pharmacies in a 60-day period.